Skip to content
Extreme Investor Network
  • Contact Us
  • Privacy Policy

MariTide

Amgen’s Weight Loss Drug MariTide Initiates Two Phase 3 Trials

March 6, 2025
Amgen weight loss drug MariTide starts two phase three trials

Amgen Makes Strides in Obesity Treatment: The Launch of MariTide Trials In the ever-evolving landscape of the pharmaceutical industry, Amgen has taken a significant leap forward in the battle against obesity with its new experimental … Read more

Categories Business News Tags Amgens, drug, initiates, loss, MariTide, Phase, trials, weight

Amgen Reports Up to 20% Weight Loss After One Year with Obesity Drug MariTide

November 26, 2024
Amgen says obesity drug MariTide caused up to 20% weight loss after a year

Amgen’s MariTide: A New Contender in the Weight Loss Drug Market At Extreme Investor Network, we take pride in delivering the latest and most comprehensive business news that keeps you ahead of the curve. Today, … Read more

Categories Business News Tags Amgen, drug, loss, MariTide, Obesity, Reports, weight, Year

Categories

Recent Posts

  • Ulli Schulz Explores the Evolution of 3D Design in Conversation with Render NetworkJune 13, 2025
  • Kenvue Considers Divesting Certain Skin Health and Beauty Brands, Sources ReportJune 13, 2025
  • Natural Gas Price Outlook: Stabilizes at Crucial Moving Average SupportJune 13, 2025
  • Carter Worth’s Insights on the Future Movements of Oil Prices According to the ChartsJune 13, 2025
  • Character.AI Unveils Framework for Assessing Engaging Writing ModelsJune 13, 2025
  • Analysis: Trump’s Tax Cut Bill May Hinder U.S. Critical Minerals ProjectsJune 13, 2025
  • Gold Price Outlook: Bullish Momentum and Patterns Point to New HighsJune 13, 2025
  • JBS Brazilian Meat Company Launches IPO in the U.S.June 13, 2025
  • Bank of America: S&P 500 Overvalued Across All 20 Metrics It MonitorsJune 13, 2025
  • Market Insights – June 13, 2025June 13, 2025

Archives

© 2025 Extreme Investor Network

Usermaven | Website analytics and product insights